MACITENTAN AS A NOVEL THERAPY TO REDUCE HEMOPTYSIS IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH UNREPAIRED TETRALOGY OF FALLOT IN AN ADULT

被引：0
|
作者：
Heredia, David L. [1 ]
Cossio, Moises [1 ]
机构：
[1] Virginia Tech Caril, Roanoke, VA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2021年 / 77卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2748 / 2748
页数：1
相关论文
共 50 条
  • [21] Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities
    McLaughlin, Vallerie V.
    Sitbon, Olivier
    Chin, Kelly M.
    Galie, Nazzareno
    Hoeper, Marius M.
    Kiely, David G.
    MacDonald, Gwen
    Martin, Nicolas
    Mathai, Stephen C.
    Peacock, Andrew
    Tawakol, Ahmed
    Torbicki, Adam
    Noordegraaf, Anton Vonk
    Rosenkranz, Stephan
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (11) : 2379 - 2391
  • [22] Therapy With Inhaled Treprostinil, Macitentan, and Tadalafil/Riociguat in High-Risk Pulmonary Arterial Hypertension
    El-Kersh, Karim
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (05) : E499 - E502
  • [23] Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension
    Gruenig, Ekkehard
    Jansa, Pavel
    Fan, Fenling
    Hauser, Jakob A.
    Pannaux, Matthieu
    Morganti, Adele
    Rofael, Hany
    Chin, Kelly M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (04) : 473 - 484
  • [24] Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model
    Markus Hoenicka
    Svitlana Golovchenko
    Leonie Englert
    Mirjam Spaeth
    Levani Shoshiashvili
    Christian Großer
    Hans-Stefan Hofmann
    Michael Ried
    Cardiovascular Drugs and Therapy, 2019, 33 : 287 - 295
  • [25] Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model
    Hoenicka, Markus
    Golovchenko, Svitlana
    Englert, Leonie
    Spaeth, Mirjam
    Shoshiashvili, Levani
    Grosser, Christian
    Hofmann, Hans-Stefan
    Ried, Michael
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (03) : 287 - 295
  • [26] Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
    Sidharta, Patricia N.
    Kraehenbuehl, Stephan
    Dingemanse, Jasper
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (03) : 437 - 449
  • [27] Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension
    Tahara, Nobuhiro
    Dobashi, Hiroaki
    Fukuda, Keiichi
    Funauchi, Masanori
    Hatano, Masaru
    Ikeda, Satoshi
    Joho, Shuji
    Kihara, Yasuki
    Kimura, Takeshi
    Kondo, Takahisa
    Matsushita, Masakazu
    Minamino, Tohru
    Nakanishi, Norifumi
    Ozaki, Yukio
    Saji, Tsutomu
    Sakai, Satoshi
    Tanabe, Nobuhiro
    Watanabe, Hiroshi
    Yamada, Hidehiro
    Yoshioka, Koichiro
    Sasayama, Shigetake
    CIRCULATION JOURNAL, 2016, 80 (06) : 1478 - 1483
  • [28] Clinical use of macitentan in the treatment of connective tissue disease-associated pulmonary arterial hypertension
    Song, Xiaohui
    Sheng, Xiangrui
    Ding, Lei
    Wu, Jian
    Chang, Xin
    Zhou, Erye
    Cao, Jing
    Cheng, Tao
    Wang, Mingjun
    JOURNAL OF THORACIC DISEASE, 2024, 16 (03) : 2060 - 2069
  • [29] Switch from Bosentan to Macitentan in Adult Outpatients with Pulmonary Arterial Hypertension: A Real-World Study
    Politi, M. T.
    Caruso, N. A.
    Lescano, J.
    Farina, J. M.
    Spagnuolo, D. N.
    Ferreyra, R.
    Bortman, G. R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S166 - S166
  • [30] Novel Dual Endothelin Receptor Antagonist Macitentan Reverses Severe Pulmonary Arterial Hypertension in Rats
    Kunita-Takanezawa, Mutsumi
    Abe, Kohtaro
    Hirooka, Yoshitaka
    Kuwabara, Yukimitsu
    Hirano, Katsuya
    Oka, Masahiko
    Sunagawa, Kenji
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (05) : 473 - 480
12345